Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003647 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 3 study, sponsored by Vical.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00003647: Completed Phase 3 study, sponsored by Vical.
NCT00003647 is a Phase 3 study that has completed, run by Vical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003647, a Phase 3 study, has completed, sponsored by Vical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.
Interventions
- DRUG dacarbazine
- DRUG allovectin-7
- DRUG allovectin-7/dacarbazine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Est. Completion | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00003647 record still lists
NCT00003647 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which dacarbazine is the first listed.
NCT00003647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003647 about?
NCT00003647 is a clinical study titled "Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Randomized phase III trial to compare the eff...
What is the current status of trial NCT00003647?
This trial is currently completed. It is a Phase 3 study. The study started on 1998-07. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00003647?
The interventions under investigation include: dacarbazine (DRUG), allovectin-7 (DRUG), allovectin-7/dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00003647?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia